Clinical Trials Logo

Dyspepsia clinical trials

View clinical trials related to Dyspepsia.

Filter by:

NCT ID: NCT00251914 Completed - Dyspepsia Clinical Trials

Nexium Dyspepsia/AST

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

NCT ID: NCT00248651 Completed - Clinical trials for Dyspepsia and Other Specified Disorders of Function of Stomach

Functional Dyspepsia Treatment Trial

FDTT
Start date: October 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.

NCT ID: NCT00247715 Completed - Dyspepsia Clinical Trials

Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)

Start date: October 2003
Phase: N/A
Study type: Interventional

The purpose of this study was to determine which treatment strategy, the step-up or the step-down treatment strategy, is the most cost-effective treatment for patients with new onset dyspepsia in primary care.

NCT ID: NCT00243724 Completed - Clinical trials for Gastroesophageal Reflux

HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease

Start date: April 2005
Phase: Phase 3
Study type: Interventional

Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.

NCT ID: NCT00232102 Completed - Dyspepsia Clinical Trials

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Start date: September 2004
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.

NCT ID: NCT00232089 Completed - Dyspepsia Clinical Trials

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Start date: May 2004
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.

NCT ID: NCT00232037 Completed - Dyspepsia Clinical Trials

Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia

Start date: September 2004
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the long-term safety of tegaserod in women with symptoms of dyspepsia who have completed the core study. Tegaserod will be evaluated at 6 mg twice daily.

NCT ID: NCT00232024 Completed - Dyspepsia Clinical Trials

Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia

Start date: January 2004
Phase: Phase 3
Study type: Interventional

This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.

NCT ID: NCT00222131 Completed - Indigestion Clinical Trials

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Start date: October 2003
Phase: Phase 2
Study type: Interventional

Inhibition of gastric acid is the key to satisfactory relief of symptoms with esomeprazole in NUD patients

NCT ID: NCT00220883 Completed - Clinical trials for Functional Dyspepsia

Electrogastrogram (EGG) Reproducibility Study: EEG Readings in Normal Subjects and Dyspeptic Patients

Start date: August 2005
Phase:
Study type: Observational

The primary objective of this study is to determine whether EGG readings obtained from both normal subjects and dyspeptic patients are reproducible from one EGG recording to another on a different day. The secondary objective of this study is to determine whether the EGG readings are analyzed and diagnosed consistently when reviewed and compared by multiple blinded readers when the same tracing is reviewed.